Corrigendum to ‘Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC’ [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659]
Saved in:
Main Authors: | Tsuyoshi Hirata, MD, Yuji Uehara, MD, Taiki Hakozaki, MD, Takayuki Kobayashi, MD, Yuto Terashima, MD, Kageaki Watanabe, MD, Makiko Yomota, MD, PhD, Yukio Hosomi, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | JTO Clinical and Research Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364324001310 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC
by: Helena Bote-de Cabo, MD, et al.
Published: (2025-03-01) -
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
by: Francesca Lucibello, MD, et al.
Published: (2025-01-01) -
Cardiac calcified amorphous tumor as a potential cause of cerebral infarction: A clinical case report
by: Hyunjin Kim, MD, et al.
Published: (2025-03-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01)